In a Phase 1a escalating clinical trial, autologous mesenchymal stem cell infusion for renovascular disease increases blood flow and the glomerular filtration rate while reducing inflammatory biomarkers and blood pressure.

[1]  L. Lerman,et al.  Tissue hypoxia, inflammation, and loss of glomerular filtration rate in human atherosclerotic renovascular disease. , 2019, Kidney international.

[2]  S. Textor,et al.  Urinary mitochondrial DNA copy number identifies renal mitochondrial injury in renovascular hypertensive patients undergoing renal revascularization: A Pilot Study , 2019, Acta physiologica.

[3]  C. McCollough,et al.  Renal Adiposity Does not Preclude Quantitative Assessment of Renal Function Using Dual-Energy Multidetector CT in Mildly Obese Human Subjects. , 2019, Academic radiology.

[4]  L. Lerman,et al.  Loss of Renal Peritubular Capillaries in Hypertensive Patients Is Detectable by Urinary Endothelial Microparticle Levels , 2018, Hypertension.

[5]  N. Perico,et al.  Clinical Transplantation of Mesenchymal Stromal Cell Therapies in Nephrology , 2017 .

[6]  Yingjie Zhang,et al.  IL-17A improves the efficacy of mesenchymal stem cells in ischemic-reperfusion renal injury by increasing Treg percentages by the COX-2/PGE2 pathway. , 2017, Kidney international.

[7]  C. McCollough,et al.  Intrarenal fat deposition does not interfere with the measurement of single-kidney perfusion in obese swine using multi-detector computed tomography. , 2018, Journal of cardiovascular computed tomography.

[8]  A. Dietz,et al.  Autologous Mesenchymal Stem Cells Increase Cortical Perfusion in Renovascular Disease. , 2017, Journal of the American Society of Nephrology : JASN.

[9]  Xining Pang,et al.  Comparison of the proliferation, migration and angiogenic properties of human amniotic epithelial and mesenchymal stem cells and their effects on endothelial cells , 2017, International journal of molecular medicine.

[10]  A. Dietz,et al.  Adipose-derived mesenchymal stem cells from patients with atherosclerotic renovascular disease have increased DNA damage and reduced angiogenesis that can be modified by hypoxia , 2016, Stem Cell Research & Therapy.

[11]  C. Romei,et al.  Mesenchymal Stromal Cells Induce Peculiar Alternatively Activated Macrophages Capable of Dampening Both Innate and Adaptive Immune Responses , 2016, Stem cells.

[12]  L. Lerman,et al.  Differences in GFR and Tissue Oxygenation, and Interactions between Stenotic and Contralateral Kidneys in Unilateral Atherosclerotic Renovascular Disease. , 2016, Clinical journal of the American Society of Nephrology : CJASN.

[13]  L. Lerman,et al.  Determination of Single-Kidney Glomerular Filtration Rate in Human Subjects by Using CT. , 2015, Radiology.

[14]  H. Qiu,et al.  Interaction between mesenchymal stem cells and endothelial cells restores endothelial permeability via paracrine hepatocyte growth factor in vitro , 2015, Stem Cell Research & Therapy.

[15]  S. Textor,et al.  Management of atherosclerotic renovascular disease after Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL). , 2015, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[16]  Steven D. Hochman,et al.  Revascularization versus Medical Therapy for Renal Artery Stenosis , 2015 .

[17]  Ralph B D'Agostino,et al.  Stenting and medical therapy for atherosclerotic renal-artery stenosis. , 2014, The New England journal of medicine.

[18]  L. Lerman,et al.  Human renovascular disease: estimating fractional tissue hypoxia to analyze blood oxygen level-dependent MR. , 2013, Radiology.

[19]  L. Lerman,et al.  Stent Revascularization Restores Cortical Blood Flow and Reverses Tissue Hypoxia in Atherosclerotic Renal Artery Stenosis but Fails to Reverse Inflammatory Pathways or Glomerular Filtration Rate , 2013, Circulation. Cardiovascular interventions.

[20]  L. Lerman,et al.  Inflammatory and injury signals released from the post-stenotic human kidney. , 2013, European heart journal.

[21]  W. Weimar,et al.  Mesenchymal stem cells derived from adipose tissue are not affected by renal disease. , 2012, Kidney international.

[22]  L. Lerman,et al.  Adipose Tissue‐Derived Mesenchymal Stem Cells Improve Revascularization Outcomes to Restore Renal Function in Swine Atherosclerotic Renal Artery Stenosis , 2012, Stem cells.

[23]  David W. Johnson,et al.  Original article anti-oxidant pathways are stimulated by mesenchymal stromal cells in renal repair after ischemic injury. , 2012, Cytotherapy.

[24]  S. Morbelli,et al.  Mesenchymal stem cells impair in vivo T-cell priming by dendritic cells , 2011, Proceedings of the National Academy of Sciences.

[25]  A. Dietz,et al.  Platelet Lysate Consisting of a Natural Repair Proteome Supports Human Mesenchymal Stem Cell Proliferation and Chromosomal Stability , 2011, Cell transplantation.

[26]  Peter Carmeliet,et al.  Hypoxia and inflammation. , 2011, The New England journal of medicine.

[27]  L. Lerman,et al.  Renovascular hypertension and ischemic nephropathy. , 2010, American journal of hypertension.

[28]  L. Lerman,et al.  Preserved Oxygenation Despite Reduced Blood Flow in Poststenotic Kidneys in Human Atherosclerotic Renal Artery Stenosis , 2010, Hypertension.

[29]  M. Shimizu,et al.  Mesenchymal Stem Cells Attenuate Renal Fibrosis Through Immune Modulation and Remodeling Properties in a Rat Remnant Kidney Model , 2009, Stem cells.

[30]  C. Baigent,et al.  Revascularization versus medical therapy for renal-artery stenosis. , 2009, The New England journal of medicine.

[31]  W. Mali,et al.  Stent placement in patients with atherosclerotic renal artery stenosis and impaired renal function: a randomized trial. , 2009, Annals of internal medicine.

[32]  B. Padanilam,et al.  In Vitro Differentiation of MSC into Cells with a Renal Tubular Epithelial-Like Phenotype , 2009, Renal failure.

[33]  Krisztián Németh,et al.  Bone marrow stromal cells attenuate sepsis via prostaglandin E2–dependent reprogramming of host macrophages to increase their interleukin-10 production , 2009, Nature Medicine.

[34]  K. Cao,et al.  Phase I clinical trial on intracoronary administration of Ad-hHGF treating severe coronary artery disease , 2009, Molecular Biology Reports.

[35]  David W. Smith,et al.  Intrarenal oxygenation: unique challenges and the biophysical basis of homeostasis. , 2008, American journal of physiology. Renal physiology.

[36]  F. Barry,et al.  Murine mesenchymal stem cells suppress dendritic cell migration, maturation and antigen presentation. , 2008, Immunology letters.

[37]  O. Ringdén,et al.  Immunomodulation by mesenchymal stem cells and clinical experience , 2007, Journal of internal medicine.

[38]  J. Nielsen,et al.  Prolyl hydroxylase-1 negatively regulates IκB kinase-β, giving insight into hypoxia-induced NFκB activity , 2006, Proceedings of the National Academy of Sciences.

[39]  D. Prockop,et al.  Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. , 2006, Cytotherapy.

[40]  R. Jaenisch,et al.  HIF-1α Is Essential for Myeloid Cell-Mediated Inflammation , 2003, Cell.

[41]  S. Textor,et al.  Renal-artery stenosis. , 2001, The New England journal of medicine.

[42]  L. Fine,et al.  Is there a common mechanism for the progression of different types of renal diseases other than proteinuria? Towards the unifying theme of chronic hypoxia. , 2000, Kidney international. Supplement.

[43]  K. Matsumoto,et al.  Potential role of hepatocyte growth factor, a novel angiogenic growth factor, in peripheral arterial disease: downregulation of HGF in response to hypoxia in vascular cells. , 1999, Circulation.

[44]  P. Sheedy,et al.  Computed tomography-derived intrarenal blood flow in renovascular and essential hypertension. , 1996, Kidney international.

[45]  E. Keshet,et al.  Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis , 1992, Nature.